NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it is acquiring contract development and manufacturing organization (CDMO) Patheon for roughly $7.2 billion.

Durham, North Carolina-based Patheon offers drug development and delivery solutions to pharmaceutical and biopharmaceutical firms. The purchase provides Thermo Fisher with access to the $40 billion CDMO market, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.